血液稀释疗法联合低分子肝素治疗急性进展性卒中临床观察

THE CLINICAL OBSERVATION OF HEMODILUTION COMBINATION OF LOW MOLECULAR HEPARIN IN THE TREATMENT OF THE ACUTE ADVANCING STROKE

[目的]观察血液稀释疗法联合低分子肝素治疗进展性卒中的临床疗效。[方法]按照随机化分组原则将42例急性进展性卒中患者平均分成两组,治疗组给予低分子右旋糖苷250ml静滴,每日1次,同时予低分子肝素5000iu皮下注射,每日2次,连续10d;对照组予低分子肝素皮下注射。两组其他治疗完全相同。[结果]治疗组远期疗效较对照组明显,神经功能恢复的显著有效率明显高于后者。治疗组在治疗后Hct、Fg两项指标较对照组明显下降。[结论]血液稀释疗法联合低分子肝素更有利于阻止脑梗塞患者病情急性进展,促进神经功能恢复,而且安全、可靠,适合早期使用。

[ Objective] To observe the clinical curative effect of hemodilution combination of low molecular heparin in the treatment of the acute advancing stroke. [ Methods] 42 cases with acute advancing stroke were randomly divided into two groups. The people in treatment group were intravenous drip injected with 250ml low molecular dextran once a day, and subcutaneously injected with 5000iu low molecular heparin twice a day for 10 days. The control group was only treated with low molecular heparin. The other therapic methods were the same in two groups. [ Results] The prostecdtive efficacy of the treatment group was better than that of the control group, and the significant effective power of nervous fimctional rehabilitation in the treatment group was much higher than that of the control group. After therapy, Hct and Fg were significantly decreased in the treatment group than those of the control group. [Conclusion] The treatment of hemodilution combination of low molecular heparin was favorable for stopping the advancement of stroke and promoting the recovery of nerves function. It was safe and suitable for the early application.